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INTRODUCTION
Sexually  transmitted  diseases  (STDs)  are  a  major  cause  of 
morbidity in developed as well as developing countries.  STD incidence 
rates remain high in most of the world, despite diagnostic and therapeutic 
advances that can rapidly render patients with many STDs noninfectious 
and cure most. 
In 1996, the World Health Organization estimated that more than 1 
million people were being infected daily. About 60% of these infections 
occur in young people <25 years of age, and of these 30% are <20 years. 
Between the ages of 14 and 19, STDs occur more frequently in girls than 
boys by a ratio of nearly 2:1; this equalizes by age 20. An estimated 340 
million new cases of syphilis, gonorrhoea, chlamydia and trichomoniasis 
occurred throughout the world in 1999.
Centre for Diseases Control and Prevention (CDC) has estimated 
that  nearly  20  million  STD cases  occur  every  year,  with  half  among 
people less than 25 years.
Changing  cultural  values,  changing  sexual  morals,  increase  in 
travel, all had contributed for increase in STDs. Additionally, 
9development and spread of drug resistant bacteria (e.g., penicillin-
resistant gonococci) makes some STDs harder to cure. 
Commonly reported prevalence of Sexually Transmitted Infections 
(STI) among sexually active adolescent girls both with and without lower 
genital  tract  symptoms  include  Chlamydia (10–25%), gonorrhoea 
(3–18%),  syphilis  (0–3%),  Trichomonas  vaginalis (8–16%), 
and herpes simplex  virus  infection  (2–12%). Among  adolescent  boys 
with  no  symptoms  of  urethritis,  isolation  rates  include  chlamydia  (9–
11%) and gonorrhea (2–3%).
HERPES SIMPLEX VIRUS INFECTIONS
Herpes simplex virus is a DNA virus belonging to Herpesviridae 
family.
The word Herpes means ‘to creep’. Latency is a common property 
of the entire herpes virus.
EPIDEMIOLOGY
Genital herpes infection assumes great importance in the HIV era. 
HSV2 infections are acquired between 15 and 40 years of age. Most of 
the genital herpes are caused by HSV2; however the incidence of genital 
herpes caused by HSV1 is increasing. Men are more likely to acquire 
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HSV2  asymptomatically  than  women.  Asymptomatic  viral 
shedding is the primary mode of herpes virus transmission. 
PATHOGENESIS
A viral infection with HSV induces ballooning of cells, followed 
by degeneration of nucleus and later multinucleate giant cells are formed. 
The infected person can excrete the virus from peripheral sites, mucosal, 
genital or oral secretions.
The virus enters the abraded site, replicates, followed by retrograde 
transport to dorsal nerve root ganglion (trigeminal ganglion in HSV1 and 
sacral  ganglion  in  HSV2).  The  prior  immune  response  to  HSV1  has 
protective effect on the acquisition of HSV2.
CLINICAL MANIFESTATIONS
HSV1  infections  range  from  asymptomatic  infection  to 
symptomatic infections in the form of fever, sore throat, ulcerative and 
vesicular  lesions,  gingivostomatitis,  oedema  and  localized 
lymphadenopathy. The incubation period ranges from 2 – 12 days. HSV1 
is also known to cause primary genital herpes.
11
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PRIMARY GENITAL HERPES
Primary genital herpes can be caused by both HSV-1 and HSV-2 
and can be asymptomatic.  The clinical  features and course of primary 
genital herpes caused by both HSV-1 and HSV-2 are indistinguishable, 
but  recurrences  are  more  common  with  HSV-2.  It  is  manifested  by 
prodromal symptoms like fever, headache, malaise, myalgia, followed by 
vesicles  rupturing into ulcers.  The lesions persist  for  3 weeks without 
treatment.1
Women with primary infection manifest with lesions in vulva, the 
cervix  being variably  involved.  They  are  more  painful  and associated 
with inguinal lymphadenopathy and dysuria.
Males present  with vesicles over glans penis,  penile shaft,  inner 
aspect of prepuce, thighs, gluteal regions and perineum. 
The complications following primary herpes infection is more such 
as urinary retention, neuralgia and meningoencephalitis.
The non primary genital herpes presents with less severe symptoms 
and heals quickly.
Recurrent  herpes infections present  with less number of  lesions. 
The frequency of recurrences varies with individuals. Immunosuppressed 
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patients  have frequent  and prolonged reactivation of latent  HSV 
infection. They present with atypical manifestations like vesicles which 
coalesce into deep necrotic ulcers and vegetative plaques.
Various studies have shown that prior HSV2 infection is associated 
with acquisition of HIV infection. Asymptomatic viral shedding occurs 
more with HIV positive persons.2
LABORATORY DIAGNOSIS
1) Microscopy ( Tzanck smear)                                    
Staining of the scrapings from the floor of the ulcer and roof of 
vesicle  with  Wright  or  Leishman  stain  shows  the  presence  of 
multinucleate  giant  cells  and  epithelial  cells  containing  eosinophilic 
intranuclear inclusion bodies. It cannot differentiate between HSV1 and 
HSV2 and the sensitivity is 67%. 
2) Culture of  HSV
Herpes simplex virus infection is best confirmed by isolation of the 
virus in tissue culture. Tissue culture success is operator-dependent, but 
this modality can yield positive results within 48 hours of inoculation.
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Characteristic cytopathic effect with ballooning of cells and cell death are 
observed, and death of the entire monolayer of cells may be rapid.
o
Immunofluorescent staining of the tissue culture cells can be used 
to quickly identify HSV and can distinguish between types 1 and 2.
3) Detection of HSV antigen
a) Immunofluorescence
b) Immunoperoxidase
c) Enzyme Immuno Assay
4) Detection of HSV DNA by PCR
5) Type specific serological assays
These  assays  had  revolutionized  the  accurate  evaluation  of 
seroprevalance  of  HSV1 and HSV2,  the advantage  being detection  of 
HSV2 antibodies in the presence of HSV1 antibodies and vice versa. The 
Enzyme  Linked  Immunosorbent  Assay  (ELISA)  uses  purified  type 
specific proteins.  The sensitivity is  85 – 98% and specificity  is  >95% 
based on the kit used. 
15
HEPATITIS B INFECTION
Hepatitis B virus (HBV) infection can be either acute or chronic, 
ranging  in  severity  from  being  asymptomatic  to  symptomatic  and 
completely resolving to severe, progressive and even fatal illness.
16
1
17
EPIDEMIOLOGY
The  carrier  rate  of  Hepatitis  B  ranges  from  0.1%  to  20%  in 
different parts of the world.
TRANSMISSION
Transmission of HBV is largely from a parenteral or in apparent 
parenteral route.
Parenteral transmission:-
HBV infection  can  occur  from exposure  to  blood  from chronic 
carriers of Hepatitis B virus. HBsAg is found in low concentrations in the 
urine,  breast  milk,  vaginal  secretions,  cerebrospinal  fluid,  sweat,  tears, 
bile  and  feces.  Transmission  thus  occurs  with  blood  transfusion, 
unpasteurized  plasma  products,  needle  stick  injuries,  and  unsterile 
instruments  when  used  in  tattooing,  acupuncture,  ear  piercing  or 
dentistry.
Sexual transmission:-
It is the most important mode of HBV transmission.
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Mostly occurs with receptive anal intercourse and homosexual population 
with multiple sexual partners. Silent carriers form an important source of 
HBV transmission.
H
In apparent transmission:-
It  may  occur  in  family  through saliva,  blood tinged  fluid,  fluid 
from open wounds and patch of dermatitis.
Perinatal transmission:-
The HBsAg positive mother is likely to transmit the infection to the 
neonate in 90% of cases.
PATHOGENESIS
Immunological  factors  play  an  important  role  in  causing  liver 
disease due to HBV. Acute hepatitis is due to immune lysis.
Chronic infection is more common in immunosuppressed patients, 
patients on hemodialysis,  post renal transplant recipients,  patients with 
leprosy or leukemia and those with associated HIV infections.
CLINICAL FEATURES
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The spectrum of HBV infection during the acute phase varies from 
subclinical  hepatitis,  anicteric  hepatitis,  icteric  hepatitis  to  fulminant 
hepatic failure. 
Incubation period ranges from 40 to 140 days.
EXTRAHEPATIC MANIFESTATIONS OF HBV INFECTION
The  extrahepatic  manifestations  include  serum  sickness, 
polyarthritis nodosa, membraneous glomerulonephritis, papular 
acrodermatitis,  aplastic  anemia,  myocarditis,  pericarditis  and 
neuromuscular  complications.  These  are  believed  to  be  mediated  by 
immune complexes in circulation.
CHRONIC HEPATITIS
The chronic phase ranges from an asymptomatic carrier  state  to 
chronic hepatitis, cirrhosis and ultimately hepatocellular carcinoma.
SEROLOGICAL DIAGNOSIS
• The first serological marker to be detectable in the serum is 
HBsAg.  It  appears  during  the  incubation  period.3 HBsAg 
appears before the onset  of symptoms, peaks during overt 
disease,  and  then  declines  to  undetectable  levels  in  3-6 
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months.  Acute  HBV  infection  is  characterized  by  the 
presence of HBsAg in the serum.
• HBeAg,  HBV DNA, and  DNA polymerase  appear  in  the 
serum  soon  after  HBsAg,  and  all  signify  active  viral 
replication.  Measuring  HBV DNA with quantitative  DNA 
polymerase  chain  reaction  (PCR)  is  ideal  for  monitoring 
disease progression and effect of treatment.
• Immunoglobulin  M (IgM) anti-HBc becomes  detectable  in 
serum shortly before the onset of symptoms, concurrent with 
the onset of 
• elevation of serum aminotransferases. Over months, the IgM 
antibody is replaced by immunoglobulin G (IgG) anti-HBc .
• Anti-HBe is  detectable  shortly  after  the  disappearance  of 
HBe Ag, implying that  the acute infection has peaked and 
the disease is on the wane.
• IgG anti-HBs does not rise until the acute disease is over and 
is usually not detectable for a few weeks to several months 
after the disappearance of HBsAg. Anti-HBs may persist for 
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life,  conferring  protection;  this  is  the  basis  for  current 
vaccination strategies using noninfectious HBsAg.
• During convalescence, HBsAg and HBe Ag are cleared, and 
IgG antibodies to HBsAg, HBcAg, and HBeAg develop.
• Hepatitis  B  surface  antibody  (HBsAb)  is  a  protective 
antibody that neutralizes the virus, although the coexistence 
of HBs Ag and HBsAb has been reported in approximately 
25% of individuals  who are HBsAg positive.  HBsAb,  but 
not  hepatitis  B  core  antibody  (HBcAb),  is  detected  in 
persons who have received the hepatitis B vaccine.
• Total HBcAb, including IgM and IgG, indicates exposure to 
the virus and viral replication. HBcAb appears shortly after 
HBsAg in 
• acute disease and persists for life; therefore, HBcAb is not a 
good marker for acute disease.
• Detection  of  IgM  HBcAb  is  diagnostic  of  acute  HBV 
infection.
22
• The carrier  state  is  defined by the presence of  HBsAg in 
serum for  6  months  or  longer  after  initial  detection.  The 
presence  of  HB sAg  alone  does  not  necessarily  indicate 
replication  of  complete  virions,  and  patients  may  be 
asymptomatic and without liver damage.
• In  contrast,  chronic  replication  of  HBV  virions  is 
characterized by persistence of circulating HBsAg, HBeAg, 
and HBV DNA, usually  with  anti-HBc and,  occasionally, 
with anti-HBs. In these patients,  progressive liver  damage 
may occur.
• The major clinical role of serum HBV DNA assays is the 
assessment of the candidacy of patients with chronic HBV 
infection for antiviral therapy and their response to it. Tests 
for HBV DNA in serum rarely help in identifying HBV as 
the  cause  of  liver  disease  in  patients  who  are HBsAg-
negative; knowledge of this fact is especially important in 
patients  with  fulminant  hepatitis  B in  whom HBsAg may 
have cleared by the time they seek.
23
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CHLAMYDIA TRACHOMATIS
The  chlamydiae  are  non  motile,  gram  negative,  obligate 
intracellular bacteria.  Chlamydia trachomatis pathogens can be divided 
into at least 15 serovars. The A, B, Ba, C serovars are associated with 
hyperendemic  blinding  trachoma.  The  D –  K serovars  cause  sexually 
transmitted disease. The L1, L2, and L3 serovars cause lymphogranuloma 
venereum.
EPIDEMIOLOGY
The chlamydial infections are much more widely dispersed. The 
risk  factors  include  previous  chlamydial  infection,  recent  change  in 
partner, asymptomatic partner, failure to use barrier contraceptives, low 
socioeconomic status 5,7,8 and gonorrhea infections.
CLINICAL FEATURES
The  most  common  manifestation  is  non  gonococcal  uretheritis 
(NGU)  in  men.  It  is  characterized  by  pyuria.  NGU  is  diagnosed  by 
demonstrating  a  significant  number  of  polymorphonuclear  cells  in  the 
first catch urine or a smear prepared from a urethral swab. 
f
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Postgonoccal uretheritis occurs in men who had been successfully 
treated for gonococcal uretheritis. It can cause epididymitis in sexually 
active men. Rectal infections are also common.
In  females,  the  most  commonly  affected  site  is  the  cervix.  The 
organism can cause mucopurulent endocervicitis. Chlamydia trachomatis 
is  a  parasite  of  columnar  epithelium.  It  also  causes  sterile  pyruia  and 
ascending  genital  infection.  Acute  salphingitis  is  the  most  important 
complication of sexually transmitted chlamydial infection. 4,6,9 Chlamydia 
trachomatis is also associated with the Fitz-Hugh-Curtis syndrome.
The  Chlamydia  can  also  cause  mucopurulent  conjunctivitis  and 
pneumonia in infants 10,11,12
In lymphogranuloma venereum, the primary lesion is painless and 
often missed.10 Secondary lesions are characterized by the involvement of 
lymph nodes. Both inguinal and femoral nodes can be involved. Later it 
may lead to suppuration and rupture of the nodes, developing draining 
fistulas.  The  rare  manifestations  of  LGV include  meningitis,  arthritis, 
pneumonia and conjunctivitis.
LABORATORY DIAGNOSIS
Cytology 
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The  infection  can  be  diagnosed  by  demonstrating  typical 
intracytoplasmic inclusions on cytological examination.
i
Fluorescent antibody technique
This is based on detecting elementary bodies in smears.
Enzyme Immunoassay
In this the chlamydial antigens are detected especially chlamydial 
lipopolysaccharide.
Culture
The  most  common technique  involves  inoculation  of  specimens 
into  cycloheximide  treated  McCoy  or  other  appropriate  cell  lines. 
Intracytoplasmic inclusions can be detected either by Giemsa stains or by 
immunofluorescent staining with monoclonal  antibodies. This has high 
specificity (100%) and sensitivity.
Nucleic Acid Amplification Tests
• Polymerase Chain Reaction (PCR), 
• Ligase chain reaction, 
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• Transcription mediated amplification  
• Strand displacement assay
Serological tests
They are less useful in genital infections but play a supportive role 
in establishing diagnosis in chlamydial salphingitis or epididymitis. The 
Micro – IF test is the serological test of choice.13
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REVIEW OF LITERATURE
Gopi Thawani et al 14 from Calcutta performed a serological study 
for  sexually  transmitted  diseases  in  patients  attending  STD  clinics  in 
Calcutta. Out of 457 samples studied positivity was highest with TPHA 
(18.60%),  followed  by  chlamydia  (15.97%),  VDRL  (8.98%),  HIV 
(6.35%) and HBsAg (3.72%). A total of 37.20% samples were positive. 
Maximum  infection  was  seen  in  15-30  years  age  group  (20.13%), 
followed by 30-45 years age group (12.69%) and > 45 years age group 
(4.38%).  Single test,  two tests and four tests  positivity  was highest  in 
15-30 years  age  group but  three  tests  positivity  was  highest  in  30-45 
years  age  group.   Positivity  was  maximum  in  single  test  (65.29%) 
followed by two tests (25.88%), three test (8.24%) and four tests (0.59%). 
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Amongst  the  single  test  positive,  maximum  was  with  chlamydia 
(36.94%), followed by TPHA (30.63%) HIV  (18.91 %), VDRL (7.21%) 
and  HBs  Ag  (6.31%).  Amongst  two  test  positivity  VDRL  +  TPHA 
positivity was the highest  (45.45%). Other  combinations were TPHA+ 
chlamydia (29.54%), chlamydia + HIV (9.09%),  HBsAg + Chlamydia 
(4.55%),  TPHA + HIV (4.55%),  HBsAg +HIV (4.55%) and TPHA + 
HBsAg (2.27%). Amongst the positivity in three tests, VDRL+ TPHA + 
Chlamydia positivity was maximum (71.43%). Other combinations were 
TPHA + chalmydia + HBsAg (14.28%) and VDRL + TPHA +HBsAg 
(14.28%).  Only  one  sample  was  positive  in  4  tests  ie  VDRL + 
TPHA +HBsAg+ chlamydia and it was 15-30 years age group. Out of 
457 samples tested, 422 were males and 35 females. Positivity was also 
more in males (31.73%) than in females (5.47%).
A study by Jindal et al  15 from Amristar in the year 2007 studied 
the prevalence of HIV, HBV and HCV among 350 STD clinic attendees. 
The prevalence was 4.3% for HIV and 3.7% for HBV. Out of the 350 
patients, 2.0% had co infection of HIV and HBV.
Rishbud  et  al  16 in  the  year  2002  studied  the  prevalence  and 
incidence of HBV among patients attending three STD clinics in Pune. 
Of  the  497  participants  3.6%,  26.5%,  and  43.2%  were  positive  for 
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HBsAg,  anti-HBs,  and  anti-HBc  respectively. 72  out  of  497  (14.5%) 
participants were HIV positive. Tattooing was found to be independently 
associated with presence of core antibody. Additionally, history of being 
in commercial sex work and history of a genital ulcer were independently 
associated with a positive anti-HBc antibody test.
Rajesh  et  al17  from  Perundurai,  Tamilnadu  studied  the 
seroprevalence of HBV and HCV in patients attending STD clinic. Out of 
105 patients screened 5.71% were HBV positive and 1.90% for HCV. 
Male to female ratio was 6.6:1. Most were in the age group of 30 – 34 
years  followed  by  25  –  29  years.  None  of  their  patients  were 
symptomatic  for  the  disease.  HIV and HBV co infection was  seen  in 
2.85% patients. Also another 2.85% patients had co infection of HIV and 
genital herpes.
Singh S et al18 from Puducherry studied the seroprevalence and risk 
factors  for  transmission  of  HIV,  HBV  and  HCV  using  anti  –  HIV, 
HBsAg and anti – HCV markers in serum. The positivity rates of HIV, 
HBsAg and HCV were 23.20 per cent, 10.00 per cent and 21.10 per cent 
respectively.  The  HIV  and  HBsAg  positivity  was  higher  in  the 
reproductive age group while HCV positivity was higher in the elderly 
individuals  (>40  years).  Higher  positivity  rates  of  all  three  infections 
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were found in females,  patients engaged as drivers,  bisexuals,  patients 
with an HIV infected spouse or contact with paid partners (CSW's).
Chopra A et al19 from Amristar studied the HBsAg seroprevalence 
in Patiala. Out of 50 patients enrolled, 70% were males and 30% were 
females.  80% of the patients were in the sexually active age group of 
15-34 years. HBsAg positivity was found in 10% of cases. Out of these 
positive cases 80% were males and 20% were females and 80% of these 
cases  were  in  the  age  group of  25-34 years  while  only  20% were  in 
between the age of 35-44 years. None of these cases were below 25 years 
or above 45 years of age. 60% of these cases had sex with more than 8 
partners while 20% of each had 5-8 and 1-4 partners. VDRL test 
was positive in 38% of the cases. In VDRL positive cases 10.52% were 
HBsAg positive. Out of the remaining VDRL negative cases only 3.22% 
were positive for HBsAg.  
Ray et al20 from New Delhi analysed their STD clinic statistics for 
a period of 15 years from 1990 to 2004. In this retrospective study the 
prevalence of HIV was 2.2% for STD clinic attendees and 4.3% for STI 
cases. The seropositivity for HSV2 IgM among patients presenting with 
genital ulcers was 22.4%.  
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Aggarwal  et  al21 from  Amristar  studied  the  seroprevalence  of 
HSV1 and HSV2 antibodies among STD clinic attendees. The study was 
conducted on 250 serum samples of STD clinic patients and 50 serum 
samples of asymptomatic women to determine seroprevalence of herpes 
simplex-1  and  2  (HSV-1  and  2)  IgM  antibodies  and  HIV-1  and  2 
antibodies. The samples were also screened for syphilis by VDRL test 
and  confirmed  by  TPHA  test.  Seropositivity  of  HSV  in  STD  clinic 
patients was 44/250 (17.6%) and 12/50 (24%) in asymptomatic women. 
In 11/44 (25%) seropositive persons for HSV, HIV 1 and 2 antibodies 
were present.  In  10/44 (22.7%) HSV seropositive persons,  coinfection 
with syphilis was also present, whereas in 7/44 (15.9%) HSV seropositive 
 
persons, both HIV and syphilis were present. In the control group, 
co  infection  with  other  sexually  transmitted  infections  (STIs)  was  not 
observed.
In  a  case  control  study  done  by  KN  shivasamy  et  al22 from 
JIPMER,  Puducherry,  they  analysed  135  patients  who  attended  STD 
clinic, along with 135 age and sex matched controls. Among study group 
cases, 112 (82.9%) cases were co-infected with HSV-1 and HSV-2, 11 
(8.1%) cases were seropositive for HSV-1 alone and 3 (2.2%) cases were 
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seropositive for HSV-2 alone. In the control group, 112 (82.9%) cases 
were  co-infected  with HSV-1 and 2,  12 (9.6%)  for  HSV-1 alone  and 
1(0.8%) for HSV-2 alone. Amongst the 53 cases (73.6%) of ulcerative 
STDs, 37 cases (63%) were clinically diagnosed as having genital herpes, 
of  which 9 cases (24.3%) were of first  episode genital  herpes and 28 
cases (75.6%) were of recurrent genital herpes. In the first episode genital 
herpes group, 6 cases (66.6%) each were positive for HSV-1 and HSV-2, 
and 5 cases (55.5%) were co-infected with HSV-1 and 2. In the recurrent 
genital herpes group, 27 cases (96.4%) each were positive for HSV-1, 
HSV-2 and both HSV-1 and 2.
Barbara Suligoi et al23 did a cross-sectional study to determine the 
seroprevalence  and the risk factors for HSV-2 infection among 776 HIV-
negative  persons  attending  an  STD  clinic  in  Milan,  Italy.  All 
samples were tested with a commercial HSV type-2 specific IgG ELISA 
test.  The  HSV-2  seroprevalence  was  29.5%.  The  seroprevalence 
increased with age, yet it did not differ by gender. Among persons with a 
current STD, the seroprevalence was 44.3%. At the multivariate analysis, 
older  age was independently  associated with HSV-2 infection.  A self-
reported  history  of  genital  herpes  was  predictive  of  HSV-2  infection. 
They concluded that the agreement between history of genital herpes and 
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HSV-2  seroprevalence  was  poor;  however,  caution  should  be  used  in 
interpreting the presence or absence of a history of genital herpes as an 
indicator of the presence or absence of HSV-2 infection.
N  Langeland  et  al24 examined  the  patients  attending  a  referral 
sexually  transmissible diseases  clinic  at  Muhimbili  Medical  Centre  in 
Dar-es-Salaam,  Tanzania during  the  period  1989  to  1993  for  herpes 
simplex virus  type  2 (HSV-2)  antibodies.  An ELISA technique,  using 
glycoprotein G of HSV-2 as antigen, was used to test 294 patients' sera. 
Of  these,  126  sera  were  HSV-2  positive,  while  168  were  negative, 
yielding an overall HSV-2 prevalence of 42.9%. Sixty-three per cent of 
the women and 35.5% of the men were HSV-2 positive. Seropositivity 
rose from 8.7% in the youngest  men to 61.5% in the oldest  male age 
group, while even the youngest women aged 20 or less had an HSV-2 
prevalence of 55.6%. There was a significant positive association 
between HIV and HSV-2 seropositivity ( P =0.0006), most pronounced 
among the youngest women. 
Marco Cusini et al25 from Milan, Italy did a cross-sectional study to 
ascertain the HSV-2 prevalence among 919 persons attending an STD 
clinic  in  northern  Italy.  A  prevalence  of  24.6%  was  found  without 
differences between males and females.  Seroprevalence increased with 
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age  and  number  of  partners  during  the  previous  year.  Seroprevalence 
significantly increased with age, ranging from 14.2% among persons 25 
years or younger to 37.5% among persons older than 35 years. There was 
no  significant  difference  between  the  prevalence  found  among 
homosexual or bisexual males (22.3%) and heterosexual males (27.8%).
A large randomized controlled trial was conducted from July 1993 
to  September  1996  to  determine  the  seroprevalence  and  correlates  of 
herpes  simplex  virus  type  2  infections  (HSV-2)  in  a  geographically 
dispersed population of US among patients attending five STD clinics 
under the name Project RESPECT26.  Of 4,128 total participants,  2,348 
(56.9 percent) were male and 1,780 (43.1 percent) were female. Overall, 
1,686 (40.8 percent) of the 4,128 participants were positive for HSV-2 
antibody. HSV-2 seroprevalence was higher among women (52 percent) 
than among men (32.4 percent). Independent predictors of HSV-2 
seropositivity included female sex, black race, older age, less education, 
more lifetime sex partners, prior diagnosis of syphilis or gonorrhoea, and 
lack  of  HSV-1  antibody.  Four  additional  factors  predicted  HSV-2 
infection  in  women:  a  prior  diagnosis  of  trichomoniasis,  a  current 
diagnosis  of  trichomoniasis,  history  of  prostitution,  and  having  a  sex 
partner who had been in jail. The only additional factor predicting HSV-2 
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infection in men was a history of  being in jail.  Circumcision was not 
independently associated with HSV-2 infection. The majority of HSV-2-
seropositive  persons  (84.7  percent)  had  never  received  a  diagnosis  of 
genital herpes.
Choudhry S et  al27 from Delhi  studied the serological  profile of 
HSV2 serology among patients attending STD clinic in Delhi. The study 
enrolled 100 patients and 30 were diagnosed clinically as genital herpes. 
Out of those 30, 17 ( 56.6%) were positive for HSV2 IgM. 7 (23.33%) 
were seropositive even though the clinical features were not suggestive of 
genital  herpes.  6  (20%)  were  seronegative  even  though  clinically 
diagnosed as genital herpes. 8 patients had other concomitant diseases.  
Mahendra M Kura et al28 studied the pattern of sexually transmitted 
diseases (STD) among two hundred and fifteen consecutive first-time 
STD clinic attendees at a teaching hospital in Bombay in October 
1995. Ulcerative STD constituted 73.5% of total STD while 15.8% were 
genital discharges and 10.2% were genital growths. Ulcers in decreasing 
order of frequency were chancroid (51.9%), genital herpes (29.1%) and 
syphilis  (14.5).  76.5%  of  genital  discharges were  due  to  gonococcal 
infection. Of 182 patients tested for HBV, 16 (8.8%) were reactive for 
HBsAg.
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Joyee et al29 studied the seroprevalence of Chlamydia antibodies in 
serum and their correlation with PCR for Chlamydial antigens in genital 
swab  in  the  year  1998  to  2002  in  Government  General  Hospital  , 
Chennai. Out of 143 symptomatic patients studied  serologic positivity by 
IgM, IgA and IgG was 22.4%, 28.7% and 58.7% respectively. The PCR 
analysis showed 44 (30.8%) cases with confirmed              C. trachomatis 
infection. Seropositivity for IgM  [34.1% (15/44)] as well as IgA [40.9% 
(18/44)]   significantly  correlated  to  PCR  positivity,  while  significant 
correlation was not seen with IgG positivity. The overall seropositivity 
(IgM/IgA/IgG) in the study population was 68.5%. 
E.Paroli  et  al30 studied  the  seroprevalence  of  anti  -  Chlamydia 
trachomatis  IgG  antibodies  among  patients  attending  STD  clinic  in 
Rome, Italy. The population composed of 741 heterosexuals, 470 males 
and 271 females, and of 147 homosexual-bisexual men. The prevalence 
rates were 
60.0%  in  heterosexual  males,  50.6%  in  females  and  73.5%  in 
homosexuals-bisexuals. A positive association between age and antibody 
prevalence  was  found  in  males.  Among  heterosexuals  there  was  an 
increasing  trend  of  seropositivity  with  number  of  partners  during  the 
previous year.
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Malhotra  et  al31 from  New  Delhi  studied  the  prevalence  of 
Chlamydia trachomatis and its association with other sexually transmitted 
infections in a tertiary care centre. A total of 276 female patients with 
complaints  of  genital  discharge  or  ulcer  were  enrolled  in  the  study. 
Genital  discharge  specimens  were  collected  from  all  patients.  The 
samples were analysed for the presence of antigen and antibody by Direct 
Fluorescent  Antibody  test  (DFA)  and Enzyme Linked Immunosorbent 
Assay (ELISA), respectively. Chlamydial infection was found in 19.9% 
of  patients.(10.1%  by  DFA,  10.9%   by  ELISA).  Only  three  patients 
(1.1%)  had  both  antigen  and  antibody  positive.  The  highest  rate  of 
infections  was found in  the age group of  20 – 30 years,  the sexually 
active group.
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AIM OF THE STUDY
To determine the seroprevalence of Herpes Simplex virus (HSV1 
and HSV2), Hepatitis B and Chlamydia trachomatis among the patients 
attending the outpatient department of Institute of Venerology, Madras 
Medical College.
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MATERIALS AND METHODS
STUDY DESIGN : Cross-sectional study
SAMPLE : The study population composed of 91patients 
attending the  Outpatient department of Institute 
of Venerology, Madras Medical College, 
Chennai  from  November  2007  to  November 
2008.
INCLUSION CRITERIA:
Patients attending the OPD irrespective of symptoms.
METHODOLOGY
All  patients  included  in  the  study  were  interviewed  and  data 
regarding their  name,  age,  address,  educational  status,  occupation  and 
marital status were collected. Their chief complaints, previous illnesses, 
treatment taken and sexual history were recorded. 
A detailed general and systemic examination followed by genital 
examination was done.
If  the  patient  presents  with  ulcer,  dark  field  examination  for 
demonstration of Treponema pallidum, smear examination by Gram’s 
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staining for the demonstration of Haemophilus ducreyi and Tzanck 
smear by Leishman staining for demonstration of giant epithelial cells are 
done.
In female patients presenting with genital discharge, wet film for 
Trichomonas vaginalis and KOH preparation for candida were taken.     
In  all  study  patients,  with  informed  consent  and  aseptic 
precautions,  5  ml  blood  was  drawn  and  serum  was  separated  by 
centrifugation  and  stored  in  sterile  containers  under  refrigeration  at  
-200 C.
All  patients’  serums were routinely tested for  blood VDRL and 
HIV1 & HIV2 (ELISA).
The serum samples were tested using Enzyme Immunoassay for 
the determination of  IgM and IgG antibodies to  Herpes simplex virus 
type 1 & 2 using Novatec ELISA kits. All reagents and samples were 
brought  to  room temperature  one  hour  before  use.  The  procedure  of 
testing was as follows.
• The samples were diluted 1:100 with IgM sample diluents 
(10 µl sample + 1 ml sample IgM diluents). The controls and 
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standards  were  not  diluted  as  per  manufacturer’s 
instructions. 
•
•
• 100 µl of sample and control were then added in the wells. 
The wells were covered with the foil supplied in the kit. 
• The wells were incubated for 1 hour ± 5 min at 37 ± 1o C. 
• After incubation, the foil was removed and the contents in 
the well were aspirated. 
• Washing of  the wells  were  done with  300 µl  of  washing 
solution. The soak time between each wash cycle is < 5 sec. 
• 100 µl of conjugate was added in the wells and incubated for 
30 min at room temperature. Again the wells were washed as 
in the previous step. 
• 100 µl of TMB substrate was added and incubated for 15 
min in the dark. 
• 100 µl of stop solution was added to the wells. 
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• The  adsorbance  of  each  well  was  read  at  450  nm using 
ELISA reader. The cut off values calculated and results were 
interpreted.
HBsAg antibody  for  Hepatitis  B  was  tested  using  ERBA-LISA 
kits. The test was done as follows.
• 50 µl of sample diluents were added to each well.
• In each run, there was one blank (100 µl sample diluents + 
50 µl  conjugate),  three negative controls  and one positive 
control. 
•
•
• 50 µl of control and test specimens were added to respective 
wells. 50 µl of conjugate was added to each well. 
• The plate was covered with black cover and incubated for 60 
minutes at 20 – 37 o C. 
• The  plates  were  washed  as  per  microplate  washing 
procedure. 
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• 50 µl of colour reagent added, covered with black cover and 
incubated for 15 minutes in dark at 20 – 30 o C. 
• 100 µl of buffer solution was added to each well  and the 
adsorbance was read at 450 nm.
The serum samples were tested for Chlamydia trachomatis IgG by 
Enzyme immunoassay using Microwell  ELISA kit.  The test  procedure 
was as follows.
• 1:21 dilution of test samples were prepared by adding 10 µl 
of sera to 200 µl of sample diluents and mixed well. 
• 100 µl of diluted sera, calibrator and controls were added in 
appropriate  wells  and  incubated  for  20  minutes  at  room 
temperature. 
• The liquid from all wells were removed and washed three 
times with 300 µl of 1X wash buffer. 
•
•
• 100 µl  of  enzyme conjugate  was  added to  each well  and 
incubated for 20 minutes at room temperature. 
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• The enzyme conjugates were removed from all  wells  and 
washed as previous step. 
• 100 µl of TMB substrate was added and incubated for 10 
minutes at room temperature. 
• Then 100 µl of stop solution was added. 
• The optical density was read at 450 nm using ELISA reader 
within 15 minutes and cut off values were calculated. 
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RESULTS
Table 1:- Sex distribution among study patients.
Male 49
Female 42
The study group included 49 males  (  53.84% )  and 42 females 
(46.15%).
Table 2:- Reason for attending STD outpatient department
Symptomatic 56
Asymptomatic 35
35 patients among 91 in the study group ( 38.5% ) attended STD 
outpatient  department  for  screening  of  STD  though  they  were 
asymptomatic for those diseases.
48
Table 3:- Age distribution of study patients.
Hep B Chlamydia
Male Female Male Female
         ≤  20       _       _      2        1
       21 – 30       2       2      7        6
       31 – 40       0       1      4        7
       41 – 50       1       _      4        3
       51 – 60       _       _      1        _
Age group
HSV 1 HSV 2
Male Female Male Female
           ≤  20        1        1          _        2
         21 – 30        2         9          9       10
         31 – 40        8         8          4        8
         41 – 50         3         3          3        3
         51 – 60         1         _          1        1
Majority of the patients were belonging to the age group of 21 – 30 
years, followed by 31 – 40 years. All the four diseases studied were less 
prevalent in younger age group i.e. < 20 years and older age group i.e. 51 
– 60 years.
–
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Table 4 :- Seroprevalence of Herpes simplex virus 1 & 2 antibodies, 
HBsAg and Chlamydiae IgG antibodies.
Test Positive Percentage
HSV 1 antibodies 46 50.5%
HSV 2 antibodies 41 45.05%
HBsAg 6 6.5%
Chlamydial IgG antibody 35 38.46%
Out of 91 samples tested by each of the six tests, 46 were positive 
for HSV 1 IgM or IgG or both. Similarly 41 were positive for either one 
or both of HSV 2 antibodies. 6 were positive for HBsAg ELISA and 35 
for  Chlamydial  IgG ELISA.  Hence  the  prevalence  of  Herpes  simplex 
virus  1  infection  was  50.5%.  Similarly  the  seroprevalence  of  Herpes 
simplex virus 2 infection was 45.05%. The seroprevalence of hepatitis B 
and Chlamydial infection were 6.5% and 38.46% respectively. 
Table 5:-  Patients with co infections.
Negative for all diseases tested                         14
Positive for one disease serology                         38
Positive for two diseases serology                         28
Positive for three diseases serology                         10
Positive for four diseases serology                          1
Out of 91 patients tested, 14 were negative for HSV 1 & 2, HBsAg 
and  Chlamydial  antibodies  tested.  Only  38  were  positive  for  one 
infection. Rest of the patients had co infections.
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Table 6:-  Patients testing positive for serological test for single 
disease.
         HSV 1 antibodies                      17
         HSV 2 antibodies                      13
         Chlamydial antibody                       7
         HBsAg                       1
In patients with single infection, HSV 1 was the predominant. Only 
one patient was positive only for hepatitis B antibody and negative for the 
rest.
Table 7:-  Patients testing positive for serological tests for two 
diseases.
           Test           Positive          Percentage
HSV 1 + HSV 2              10            10.98%
HSV 1 + Chlamydia               9             9.89%
HSV 2 + Chlamydia               7             7.69%
Hep B + Chlamydia               2             2.19%
  
10 patients were found to be infected with both Herpes simplex 1 
& 2 viruses. Chlamydial infection was found to be coexisting in the rest 
of 18 patients testing positive for two disease serological tests.
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Table 8:- Patients testing positive for serological tests for three 
diseases.
Test Positive Percentage
HSV 1 + HSV 2 + Chlamydia              8          8.79%
HSV 2 + Hep B + Chlamydia              1          1.09%
HSV 1 + HSV 2 + Hep B              1          1.09%
8 ( 8.79% ) patients were found to be infected with both types of 
Herpes simplex viruses and Chlamydia.
Table 9:- Patients testing positive for the serological tests for all four 
diseases.
            Test           Positive          Percentage 
HSV 1 + HSV 2 + Hep 
B + Chlamydia
              1              1.09%
 
Only one patient was found to be positive for HSV 1 IgM, HSV 2 
IgG, HBsAg and Chlamydial IgG. He was also reactive for HIV.
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Table 10:-  Total no. of samples positive among the tests done.
Tests done No. of samples positive 
(Total tested = 91 )
Percentage
   HSV 1
   IgM 15 16.48%
   IgG 39 42.85%
   HSV 2
   IgM 11 12.08%
   IgG 35 38.46%
           HBsAg 6 6.5%
      Chlamydia IgG 35 38.46%
 
Out of the above 6 tests done, the maximum positivity was seen for 
HSV 1 IgG ELISA ( 42.85%). 38.46% samples were positive for HSV 2 
IgG and Chlamydia IgG antibody ELISA tests. Out of 91 samples tested, 
only 6 were positive for HBsAg ELISA test. 
Table 11a:-  Total no. of patients infected with Herpes simplex virus 
1 & 2.
Patients with HSV 1 infection only 25
Patients with HSV 2 infection only 21
Patients with both HSV types infection 20
Total no. of patients with HSV infection 67
Out of 91 patients tested, 67 ( 73.62% ) were infected with Herpes 
simplex virus. Out of these, 37.3% had only HSV 1 infection, 31.3% had 
only HSV 2 infection and 29.8% had both HSV 1 and 2 infections. 
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Table 11b:- Antibody type in HSV infected patients.
IgM + ve IgG + ve IgM + IgG +ve
Patients with HSV 1 infection 6 31 9
Patients with HSV 2 infection 6 30 5
Among the patients testing positive for HSV antibodies, majority 
of them were IgG positive.
Table 12:- HIV positivity among samples tested
HSV 1 HSV 2 HBsAg
Chlamydia 
IgG
IgM IgG IgM IgG
HIV +ve
N = 10
3 4 1 9 2 8
A total of 10 out of 91samples were reactive for HIV by ELISA. 
All the patients reactive for HIV ELISA were positive for one or more of 
the six tests done for this study. One patient’s sample was positive for 
HIV and all the other six ELISA tests done for this study. 
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Table 13:-  Co infections in HIV positive patients.
HSV 1 infection                    5
HSV 2 infection                    9
Hepatitis B                    2
Chlamydial infection                    8
  
2 patients had HSV 2 infection alone along with HIV infection. 
Rest of the patients had mixed infections.
Table 14:-  Other associated STIs in seropositive patients.
Associated 
disease
HSV 1 HSV 2 Hep B Chlamydia
Syphilis 4 3 _ 1
Trichomoniasis 
vaginitis
_ 1 _ 1
Bacterial 
vaginosis
5 6 _ 4
Vulvovaginal 
candidiasis
_ 2 _ _
Genital warts 4 1 _ 2
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Table 15a:-  Serological profile of symptomatic patients.
Test Genital ulcer Genital discharge
          HSV 1             10             10
         HSV 2              9             10
      Chlamydia              7              8
Out of 46 HSV 1 antibody positive samples, 10 ( 21.7% ) were 
from patients with genital  ulcers.  Similarly 21.9% HSV 2 seropositive 
samples  were  from  patients  with  ulcers.  8  (  22.8%  )  of  Chlamydial 
antibody seropositive patients had genital discharge.
Table 15b:-  Serological profile of asymptomatic patients.
Serological test Total positive
HSV 1 antibodies 13
HSV 2 antibodies 14
Chlamydial antibody 15
Among the asymptomatic patients,  13 samples were positive for 
HSV  1  antibodies,  14  for  HSV  2  antibodies  and  15  for  Chlamydial 
antibody. Out of 35 asymptomatic patients, 5 ( 14.3% ) had HSV 1 
infection,  6  (17.1%  )  had  HSV  2  infection,  8  (22.8%  )  had 
Chlamydial infection and 9 ( 25.7% ) had co infections.
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Table 16:-  Patients with genital discharges
Speculum 
examination
HSV 1 
IgM/IgG/ both 
+ve
N = 21
HSV 2 
IgM/IgG/both +ve
N = 24
Chlamydia 
IgG +ve
N = 17
Cervix healthy 6 4 4
Cervix 
hypertrophied
_ 2 2
Cervical erosions 2 3 3
Speculum examination in females testing positive for HSV 1 & 2 
antibodies and Chlamydial antibody revealed a healthy cervix in majority 
of them. Erosions were seen in 2 ( 9.5% ) females with HSV 1 infection, 
3  (  12.5% )  with HSV 2 infection  and 3 (  17.6% )  with Chlamydial 
infection.
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Table 17:-  Urban vs Rural distribution of study patients.
URBAN RURAL
Male Female Male Female
          HSV 1 17 14 8 7
          HSV 2 10 15 7 9
          Hep B 3 3 _ _
        Chlamydia 11 11 7 6
In  all  the  four  disease  groups,  patients  from urban  areas  were 
predominant than rural areas. Out of patients positive for either one or 
both of HSV 1 antibodies, 31(67.4% ) were from urban areas whereas 
only 15 (32.6%) were from rural areas. Similarly for HSV 2 antibodies 
positive patients, 25 (60.9% ) were from urban areas and 16 (39.02% ) 
from rural areas. All the 6 patients tested positive for HBsAg were from 
urban  background.  The  similar  trend  was  seen  in  Chlamydia  antigen 
positive patients i.e. 22 ( 62.8% ) were from urban areas and 13 ( 37.1% ) 
were from rural areas.
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Table 18:-  Marital status of seropositive patients.
Married Unmarried Widow
Male Female Male Female
HSV 1 12 19 13 1 1
HSV 2 10 21 7 _ 3
Hep B 1 3 2 _ _
Chlamydia 12 14 6 _ 3
Married  men and women were  predominant  among seropositive 
patients. Out of 46 samples positive for either of HSV 1 antibodies, 31 
(67.4% ) were of married patients. In HSV 2 serology positive patients, 
75.60% were married; in HBsAg positive patients, 66.66% were married; 
in Chlamydial IgG antigen positive patients, 74.3% were married. Among 
married patients,  married women were predominant than married men. 
Among  unmarried  patients,  all  seropositive  samples  were  from  male 
patients except for one female patient positive for HSV 1 IgM antibody. 
There were no widowers in the study.
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The married : single ratio for HSV 1 males 1 : 1.08, females 9.5 : 1; HSV 
2  males  1.4  :  1,  females  7  :  1;  HBsAg  males  1  :  2;  females  3  :  1; 
Chlamydia males 2 : 1, females 3.5 : 1.
Table 19:-  Occupational status of seropositive patients.
Occupation HSV 1 HSV 2 Hep B Chlamydia
Agricultural 
coolie
       1        3         _        1
Driver        3        4         _        4
Housewife       14       11         1        7
Labourer        9       10         1        8
CSW        _        1         2        2
Shopkeeper        5        2         1        2
Watchman        1         1         _        1
Electrician        3         _         _        _
Fruit seller        1         1         _        1
Security        1         1         _        2
Police        1         1         _        _
Student        1         _         _        1
Hotel worker        1         2         1        1
Unemployed        1         _         _        _
Others        4        4         _             4
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Both  skilled  and  semiskilled  labourers  were  found  to  be 
seropositive in equal proportions. Among the females affected, most were 
housewives.
Table 20:-  Educational status among the test positive patients.
Educational
   Status
     HSV 1 
IgM/IgG/both
       +ve
     HSV 2 
IgM/IgG/both
+ve
HBsAg 
+ve
 Chlamydia
   IgG +ve
Uneducated          9          8           1          7
1st – 5th std.        10         11           2         10
6th – 12th std.      26         21          3         17
Graduate       1          1          _          1
Most of the patients testing positive for the tests were educated. 
56.5%  of  HSV  1  ELISA  positive  patients,  51.2%  of  HSV  2  ELISA 
positive patients, 50% of HBsAg positive patients, 48.57% of Chlamydial 
IgG positive patients studied upto secondary school.
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DISCUSSION
The  seroprevalence  of   HBsAg,  HSV  1  antibodies,  HSV  2 
antibodies and Chlamydial antibodies among patients who attended the 
STD clinic were 6.5%, 50.5%, 48.05% and 38.46% respectively.
The seroprevalence of HBsAg in this study was 6.5%. Two studies 
from a similar south Indian population showed similar seroprevalence. A 
study  by  Rajesh  et  al17 from  Perundurai,  Tamilnadu  in  105  patients 
showed a prevalence of 5.71%. A study from Puducherry by Singh et al18 
showed  a  prevalence  of  10%  in  270  patients  studied.  Studies  from 
northern  India  showed  a  lesser  seroprevalence.  The  seroprevalence  of 
HBsAg in 497 patients studied by Risbud et al16 from Pune was 3.6%. 
Gopi  Thawani  et  al14 from  Kolkata  studied  457  patients  and  the 
seroprevalence was 3.72%. Jindal et al15 studied 350 patients in Amristar 
and the seroprevalence of HBsAg was 3.7%. The difference between each 
study could be due to number of patients screened and the differences in 
exposure  to  the  virus  among  those  patients.  The  difference  in 
seroprevalence  was  noted  in  community  surveys  also.  A  community 
cluster  survey32 in  Tamilnadu  in  1998  screened  1981  healthy  blood 
donors and the community prevalence of HBsAg was found to be 5.7%. 
A community  survey33 of  20,000 healthy  blood donors  from different 
cities in Uttar Pradesh showed a lesser prevalence of 2.25%.
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Among  91  patients  tested,  67  were  found  to  be  infected  with 
Herpes simplex virus. 25 ( 37.3% ) had HSV 1 infection alone and 21 
(31.3% ) had HSV 2 infection alone. Combined infection was seen in 20 
(29.8% ) patients. The seroprevalence of HSV 1 and HSV 2 irrespective 
of single or combined infection was 50.5% and 45.05% respectively.
Among the 91 samples tested for HSV antibodies, HSV 1 IgM was 
positive in 16.48% samples, HSV 1 IgG was positive in 42.85% samples, 
HSV 2 IgM was positive in 12.08% samples and HSV 2 IgG was positive 
in 38.46% samples. Nearly half of the samples tested were positive for 
IgG of  both  types  of  herpes  viruses  showing  that  past  infection  was 
common than recent infection. 
A study by Shivasamy et al22 from Puducherry showed that 91.5% 
were seropositive for HSV-1, 85.1% were seropositive for HSV-2, 82.9% 
were co-infected with HSV-1 and HSV-2,  8.1% were seropositive  for 
HSV-1 alone and 2.2% were seropositive for HSV-2 alone.
A study from Amristar by Aggarwal et al21 showed a seropositivity 
of 17.6%. The seroprevalence of HSV 2 in Italy was 24.6% according to 
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Marco Cusini et al25. In Tanzania, it was 42.9% according to Langeland et 
al24.   
.
This difference in seroprevalence could be explained by the Smith 
and  Robinson’s34 global  review  of  type-specific  HSV  prevalence  in 
different  geographic  areas.  According  to  them,  HSV-2  prevalence  is 
highly  variable  and  depends  on  many  factors  including  country  and 
region of residence, population subgroup, sex and age. HSV-2 prevalence 
is  in  general  higher among higher risk sexual  behavior  groups and in 
women  than  men.  Its  seroprevalence  is  strongly  associated  with  age, 
increasing from negligible levels in children younger than 12 years to as 
high as 80% among high-risk population. In a given population and age 
group,  HSV-1  prevalence  is  almost  always  greater  than  HSV-2 
prevalence.
In this study HSV 1 seroprevalence is slightly higher than HSV 2 
seroprevalence.
The seroprevalence of Chlamydia was 38.46% in this study. The 
seroprevalence of Chlamydial IgG in Chennai according Joyee et al29 was 
58.7%. A similar study by Malhotra et al31 showed a prevalence of 10.9% 
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using antibody detection methods. These differences could be due to the 
difference  in  the type of  antigens  used  in  the kits  and the  population 
studied.
s
The prevalence of Chlamydia trachomatis infection is found to be 
differing according to the population studied and diagnostic methods. The 
prevalence of Chlamydia by antigen testing was found to be 24.5% in 
Chennai by Joyee et al35 and 16% by Dowe et al36 in high risk STD clinic 
attendees.
Out of 91 patients studied, 14 patients (15.3%) were negative for 
all the tests. Out of rest positive, 38 patients (41.7%) were positive for 
single  infection.  Rest  39  (42.8%)  had  mixed  infections.  HSV 1  and  
HSV 2 were the most common mixed infection which was seen in 10 
patients. HSV 1, HSV 2 alone or both infections were seen in 37 out of 
39 patients with mixed infections. Herpes simplex virus infection was the 
most  common sexually  transmitted infection in this study. A study by 
Kavina BK et al37 from Ahmedabad concluded that herpes infection was 
found to be the most common STD among patients attending STD clinic. 
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Out of 6 patients positive for HBsAg, one patient was positive for 
hepatitis B alone, the rest had mixed infections.  
The  HIV  seropositivity  was  10.9%  in  this  study.  Except  for  2 
patients, remaining 8 patients had mixed infections. HSV 2 infection was 
found in 9 out of 10 patients. Chlamydia infection was seen in 8 HIV 
positive patients.
p
Wald  A  et  al38 had  suggested  that  HSV-2  infection  could 
significantly enhance the rates of sexual transmission and acquisition of 
human immunodeficiency virus in developing countries. Similarly HSV 2 
infection was significantly higher in HIV positive patients.
The second most common infection in HIV positive patients was 
Chlamydial  infection.  Out of  35 patients  with Chlamydial  infection,  8 
(22.8% ) were HIV positive. A similar study in Chennai by Joyee et al39 
had  reported  29.5%  of  the  Chlamydia  infected  patients  were  HIV 
positive.
Co  infections  of  STI  were  seen  in  42.8%  of  patients  studied. 
Among patients with two infections, HSV 1 and HSV 2 co infection was 
common  and  was  seen  in  10.98%  of  cases.  In  patients  with  three 
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infections,  co  infections  of  HSV  1,  HSV  2  and  Chlamydia  was  the 
commonest. Out of the 91 patients studied, only one had all the four STI 
studied viz. HSV 1, HSV 2, Chlamydia, Hepatitis B. 
A study by Thawani G et al14 in Kolkata also reported that 34.7% 
of the patients had co infection of STI in their serological survey of STD 
clinic  patients.  Infection  with  one  STI  increases  the  risk  of  acquiring 
another STI.
a
HSV 1 and HSV 2 co infection was seen in 20 of 67 seropositive 
patients. Out of 41 patients who were seropositive for HSV 2, 20 (48.8%) 
had HSV 1 infection. HSV 1 antibodies were said to be protective against 
HSV 2 infection. But the higher prevalence of HSV 2 in patients with 
HSV 1 antibodies was noted in this study. In a study by Fujie Xu41 from 
US also had found that approximately 76% of persons who had HSV-2 
antibody  also  had  HSV-1  antibody. They  concluded  that  the 
seroprevalence  of  HSV-1  and  age  at  infection  may  influence  the 
epidemiology of  clinical  genital  herpes,  even if  prior  HSV-1 infection 
does not prevent HSV-2 infection.
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In this study the co existence of HSV and Chlamydia was seen in 
many patients. Deka S et al40 had said that HSV 2 co infection stimulates 
the formation of persistent chlamydiae. Their study  suggested that HSV 
attachment  and  entry  can  provide  the  necessary  stimulus  to  alter  
C. trachomatis development.
Most of patients were in the age group of 20 – 30 years, followed 
by age group of 30 – 40 years. This younger age predominance was seen 
in  both males  and females.  Many studies had found that  the sexually 
active age group of 20 – 40 years had more STIs. 
a
Thawani G et al14 had found that maximum infection was seen in 
15-30 years age group, followed by 30-45 years age group and > 45 years 
age group. Chopra et al19 studied the seroprevalence of HBsAg and found 
that 80% of the cases were in the age group of 25-34 years while only 
20% were in between the age of 35-44 years.
Aggarwal et al21 had reported that 45.5% of the HSV seropositive 
patients were between 21 and 30 years. The similar picture is seen in this 
study group. HSV 2 seroprevalence was higher in males and females of 
21 – 30 age groups.
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Among the 35 asymptomatic patients, only 7 ( 20% ) were negative 
for serological tests of Herpes simplex virus and Chlamydia. 13 of 35 
patients had HSV 1 infection and 14 of 35 patients had HSV 2 infection. 
Aggarwal  et  al21 also  had  found  24%  prevalence  of  HSV  1  and  2 
antibodies in asymptomatic females. 
The seropositivity of STIs was only slightly higher in married men 
than  unmarried  men.  But  the  difference  was  large  in  married  vs. 
unmarried women. Ray et al had identified that there was increase in the 
incidence  of  STI  among married  patients  than  single  patients  in  their 
retrospective analysis of patients over 15 years.  Their married females 
had 4.5 times higher incidence of STIs than single females. Saikia et al42 
in their study of STDs in Assam had found that prevalence of STIs 
among married vs. unmarried men was in the ratio of 1 :  1.15 and in 
females was 2.3 : 1. Among the married individuals, extramarital sexual 
relation to the extent of 68% was observed in their study.
Majority of the seropositive patients in this study were educated 
and had upto secondary level of education. Only 14% of the STD patients 
were uneducated and 36.4% studied upto secondary school in Bangalore 
city according to Ramesh K et al43 in their study of STDs in Bangalore 
city. In a study by Ray et al20, 46.5% of patients had secondary education.
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Approximately  60%  of  patients  with  HSV  and  Chlamydial 
infection and 100% of patients with hepatitis B infection were from urban 
background. This may be due to the study being done in an urban hospital 
setting  or  lack  of  health  awareness  among  urban  slum  and  migrant 
populations.
No specific  occupational  predominance was noted in  this  study. 
The seroprevalence was more or less equal in unskilled and semiskilled 
labourers.  Many of the affected females were housewives. The similar 
pattern was seen in a study by Ray et al20 in Delhi in which 66.2% of 
male  patients  were  semiskilled  labourers  and  85.8% of  females  were 
housewives.
h
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CONCLUSION
• The  seroprevalence  of   HBsAg  is  6.5%,  Herpes  simplex 
virus  1  antibodies  is  50.5%,  Herpes  simplex  virus  type  2 
antibodies is 45.05% and Chlamydial antibody is 38.46%.
• Most of the HSV antibodies are of IgG type indicating past 
infection.
• Infection with one STI increases the risk of acquiring other 
STIs. 42.8% of the patients studied had co infections.
• HSV 1 and HSV 2 are the most common co infections.
• The seroprevalence of HIV in this study is 10.9%. HSV 2 
and  Chlamydia  are  the  most  common  co  infections  in 
patients with HIV.
• The prevalence of HSV 1 and 2 antibodies and Chlamydial 
antibodies are high in asymptomatic patients.
• Most of the seropositive patients in this study are married, 
educated upto secondary school and urban residents.
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PROFORMA
Name:                                           Age:                                             Sex: 
STD no:  
Address:
Occupation:
Educational status:  uneducated / up to 5th / 6 – 12th / graduate 
Marital status: married / unmarried / widow / widower
Complaints
• Ulcer
• Discharge
• Others
If ulcer genitalia / H/O previous ulcer genitalia
• Duration of the ulcer
• H/O evolution of the  ulcer
• Prodromal symptoms: present /  absent
• H/O recurrences: present / absent
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• No of recurrences per year
• Any similar complaints in the partner
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PAST HISTORY
• Past H/O any venereal disease
• H/O jaundice
• H/O blood transfusion
• H/O surgery 
TREATMENT HISTORY
PERSONAL HISTORY
• Smoking / alcohol / tobacco chewing
• H/O intravenous drug abuse
MENSTRUAL HISTORY
LMP                         Regular / irregular cycles
OBSTETRIC HISTORY
• Total no. of children / Last child birth
• H/O abortion - If yes – 1) spontaneous / induced   2) duration of 
gestation
• H/O ectopic pregnancy / infertility / sterilization
SEXUAL HISTORY
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• H/O recent exposure
• Marital contact
• Premarital contact
• Extramarital contact
E
SEXUAL ORIENTATION
Heterosexual / homosexual / bisexual
GENERAL EXAMINATION
Pallor / icterus / cyanosis / clubbing / lymphadenopathy
Pulse rate / BP
SYSTEM EXAMIANATION
• CVS
• RS
• ABDOMEN
• CNS
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• SKIN AND MUCOSA
• MUSCULOSKELETAL EXAMINATION
EXAMINATION OF GENITALIA
FEMALES 
• Inguinal nodes
• External urethral meatus
• Speculum examination: 
• Cervix – Healthy / Hypertrophied / Erosion
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• Discharge – scanty / moderate / profuse
Mucoid / mucopurulent / purulent
Foul smelling
• Ulcer – single / multiple, painful / painless, soft / indurated, bleeds 
on touch 
• Skin and mucosa
• Bones and joints
MALES 
• Circumcised / uncircumcised
• Ulcer – single / multiple, painful / painless, soft / indurated, bleeds 
on touch
• Uretheral discharge / subprepucial discharge
• Inguinal nodes
• Skin and mucosa
• Bone and joints
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INVESTIGATIONS
• Blood VDRL
• TPHA
• ELISA for HIV
Genital discharge
• Wet film for TV
• KOH for Candida
• Gram stain
• Uretheral smear ( males ) – Gonococci
• Vaginal and endocervical smear – clue cells / candida / lactobacilli 
/ Gonococci
Genital ulcers
• Dark field for Treponema pallidum
• Tzanck smear
• Leishman’s stain for Donovan bodies
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Consent
I  am  willing  for  clinical  examination  and  blood  sampling  for 
serology  of  HSV  1  &  2,  hepatitis  B  and  Chlamydia  antibodies.  The 
procedures have been explained to me.
                                                                              
Date:                                                                                          Signature:
                                                                                                      Name:
Blood for 
 HBsAg
 HSV1 & HSV2  IgM & IgG antibodies
 Chlamydia IgG antibodies
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